Premium
In vivo recovery and safety of human factor VIII product AAFACT ® in patients with haemophilia A
Author(s) -
Vossebeld P. J. M.,
Tissing M. H.,
Van Den Berg H. M.,
Leebeek F. W. G.,
De GoedeBolder A.,
NovÁkovÁ I. R. O.,
Gerrits W. B. J.,
Peters M.,
Koopman M. M. W.,
Faber A.,
Hiemstra H.,
Grob P.,
Strengers P. F. W.
Publication year - 2003
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.2003.00730.x
Subject(s) - medicine , in vivo , haemophilia a , haemophilia , adverse effect , blood product , haemophilia b , postmarketing surveillance , coagulation , factor ix , antibody , pharmacology , immunology , surgery , microbiology and biotechnology , biology
Summary. AAFACT ® , a monoclonal purified, solvent/detergent treated human plasma‐derived coagulation factor VIII concentrate obtained from plasma of voluntary, non‐remunerated blood donors, is manufactured and marketed in the Netherlands by Sanquin Plasma Products since 1995. In a postmarketing surveillance study, 70 previously treated haemophilia A patients were included (73% severe, 14% moderate and 13% mild haemophilia A). Most of these patients were followed during 4 years for the appearance of adverse events, possible transmissions of blood‐borne viruses and the occurrence of antibodies against FVIII. The efficacy of treatment was determined in each patient by the in vivo recovery of FVIII. During this study, only six adverse events, possibly related to the use of AAFACT ® , were reported. None of these were indicated as serious. Transmissions of HIV, HAV, HBV and HCV in the seronegative patients have not been observed. In none of the patients, inhibitors to FVIII were detected. The in vivo recovery of FVIII during this study was not different from the in vivo recovery observed in eight patients during the preregistration study. There was a correlation of in vivo recovery with age and body weight. From these results, we conclude that the clinical usage of this human plasma‐derived FVIII product is efficient and safe.